Low dose albumin for the prevention of renal impairment following large volume paracentesis in cirrhosis. by Hussain, Waqar et al.
eCommons@AKU
Department of Medicine Department of Medicine
March 2015
Low dose albumin for the prevention of renal











Agha Khan University, hasnain.alishah@aku.edu
Follow this and additional works at: http://ecommons.aku.edu/pakistan_fhs_mc_med_med
Part of the Gastroenterology Commons
Recommended Citation
Hussain, W., Khalid, A. B., Usmani, T., Ghufran, A., Shah, S. (2015). Low dose albumin for the prevention of renal impairment
following large volume paracentesis in cirrhosis.. Pakistan journal of medical sciences., 31(3), 592-596.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_med_med/254
592   Pak J Med Sci   2015   Vol. 31   No. 3      www.pjms.com.pk
Open Access
INTRODUCTION
 Ascites is one of the most common complication 
of cirrhosis that leads to hospital admissions.1 The 
mainstay of ascites treatment is dietary sodium 
restriction and diuretics.2 However for ascites 
which is tense and in those patients where ascites 
is refractory to  diuretic treatment, large volume 
paracentesis (LVP) of ascitic fluid provides rapid 
and effective relief of symptoms.3 The safety of 
performing serial LVP has been demonstrated  and 
guidelines recommend serial LVP  as one of the 
treatment options for refractory ascites.4
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Low dose albumin for the prevention of renal impairment 
following large volume paracentesis in cirrhosis 
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ABSTRACT
Objectives: To evaluate the effect of low dose Albumin i.e. 4 grams per litre of ascitic fluid after large 
volume paracentesis (LVP) for the prevention of paracentesis induced circulatory dysfunction (PICD) related 
renal impairment in cirrhosis.
Methods: Case records of all patients with cirrhosis who underwent LVP from January 12th, 2011 till 
December 29th, 2013 were reviewed. Patients were excluded if they had spontaneous bacterial peritonitis, 
creatinine >1.5 mg/dl, hepatoma or if volume of ascitic fluid removed was <5 litres. Data including age, 
gender, cause of cirrhosis, CTP score and volume of ascitic fluid drained were noted. In addition serum 
creatinine and serum sodium at baseline and one week post paracentesis were recorded.
Results: Two hundred and fourteen patients with cirrhosis underwent LVP during the study period. One 
hundred and thirty nine patients met the inclusion criteria and were analyzed. Patients were divided 
into two groups based on the amount of albumin given. The amount of albumin given was 25 grams and 
50 grams while the volume of ascitic fluid removed were 6.2±1 litres and 10.4±1.5 litres in groups A and 
B respectively. One hundred and eight patients were in group A while thirty one patients were in group B 
respectively. Both groups received albumin at a dose of 4 grams per litre of ascitic fluid removed. Mean 
age in both groups were 53 years. Hepatitis C was the commonest etiology in both the groups, followed by 
Hepatitis B. More than 70% patients in both the groups were in child class C. Serum creatinine at baseline 
and one week post LVP was 1.04±0.24 mg/dl and 1.07±0.35 mg/dl in GROUP A while 1.11±0.23 mg/dl and 
1.41±0.94 mg/dl in GROUP B. (P value 0.35). Similarly, serum sodium at baseline and one week post LVP 
was 130 ±5.6 meq/lit and 129.6±5.9 meq/lit in GROUP A while 127.6±5.8 meq/lit and 128±6.2 meq/lit in 
GROUP B respectively. (P value 0.14)
Conclusion: This study suggests that 4 grams of albumin per litre of ascitic fluid drained is effective in 
preventing the PICD related renal impairment following large volume paracentesis in cirrhosis
KEY WORDS: Ascites, Child turcotte pugh score, Large volume paracentesis, Paracentesis induced 
circulatory dysfunction. 
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Low dose albumin for prevention of renal impairment
 Removing large volume of ascitic fluid without 
volume expansion may lead to significant 
hemodynamic changes; a syndrome termed 
paracentesis induced circulatory dysfunction 
(PICD). PICD is associated with marked activation 
of renin angiotensin aldosterone system and is 
associated with renal impairment, re-accumulation 
of ascites and shortened survival.5 PICD can occur 
in upto 80% of patients not receiving plasma volume 
expansion. Various agents have been tried to prevent 
PICD during LVP. Amongst all of them albumin 
has been the most widely agent used so far and is 
found to be highly effective in preventing PICD 
following LVP.6-8 Albumin administration however 
has some potential side effects. Infusion of albumin 
markedly increase albumin degradation9 and 
albumin is prohibitively expensive.10-12 Moreover 
albumin administration post LVP does not offer 
a survival benefit as compared with those treated 
without albumin or with other plasma expanders. 
In prior studies, albumin has been administered at 
a dose of 6-8gm/litre of ascitic fluid removed.5,13 
Only scarce literature exists comparing different 
doses of albumin, therefore American association 
of the study of liver diseases (AASLD) guidelines 
also state that albumin can be considered at a dose 
of 6-8 gm/litre of ascitic fluid removed.4
 The aim of this study was to evaluate the effect of 
low dose albumin use for the prevention of PICD 
related renal impairment following large volume 
paracentesis in cirrhosis.
METHODS
Operational definitions: Renal failure is defined 
as >50% in the serum creatinine concentration to a 
value ≥1.5mg/dl from the baseline.13 Hyponatremia 
is defined as decrease in serum sodium to more 
than 5meq/litre to a level less than 130meq/litre.13
 All patients of decompensated cirrhosis with 
tense ascites who underwent LVP between January 
12th, 2011 till December 29th, 2013 at the section of 
gastroenterology, department of Medicine at the 
Aga Khan University Hospital were included in 
the study which was approved by the Aga Khan 
University Ethical Review Committee.
 We included all patients with cirrhosis and 
tense ascites requiring LVP, age between 18 to 75 
years who underwent paracentesis of >5 litres. 
The exclusion criteria were: Known coronary heart 
disease, congestive cardiac failure, creatinine more 
than 1.5mg/dl, spontaneous bacterial peritonitis, 
sepsis or variceal bleed within 7 days of LVP, 
hepatocellular carcinoma, platelet count less than 
30,000 and malignant ascites.
 The diagnosis of cirrhosis was made on clinical, 
biochemical and radiological features. A base line 
biochemistry panel including serum creatinine, 
serum sodium and potassium were obtained before 
paracentesis. Paracentesis was performed from 
right or left iliac fossa under sterile conditions. 
An albumin 4 gram per liter was administered 
immediately at the end of paracentesis. During and 
half an hour after paracentesis heart rate and blood 
pressures were monitored. After the administration 
of albumin the subjects were discharged and were 
asked to follow in the gastroenterology clinics 
after one week with biochemistry profile. On call 
physician assessed every patient for any local 
complications as well as for hemodynamic stability 
before discharge. At clinic visit, patient’s serum 
creatinine and sodium were compared with pre 
paracentesis profile.
Statistical Method: Results were expressed as mean 
+ standard deviation for continuous variables (e.g., 
Age) and number (percentage) for categorical data 
(e.g. Gender etc.). Groups were compared using 
the independent sample t-test, Pearson Chi-square 
test and Fisher Exact test where ever appropriate. 
A P-value of <0.05 was considered as statistically 
significant. All p-value were two sided. Statistical 
interpretation of data was performed by using the 
computerized software program SPSS version 19.0.
RESULTS
 Two hundred and fourteen patients underwent 
LVP during the study period. Seventy five 
patients were excluded out of which eleven had 
malignant ascites, forty three had serum creatinine 
>1.5 mg/dl. The data was incomplete for twenty 
one patients. Total One hundred and thirty nine 
patients were analyzed. (Fig.1). They were divided 
in two groups on the basis of amount of albumin 
Total Patients with LVP
214 Patients
Excluded
Malignant Ascites --- 11 patients
Creatinine > 1.5 ---  43 patients
Incomplete data ----- 21 patients
Included
139 patients
given. The amount of albumin given was 25 grams 
and 50 grams while the volume of ascitic fluid 
removed were 6.2±1 and 10.4±1.5 in groups A and 
B respectively. One hundred and eight patients 
were in group A while thirty one patients were 
in group B respectively. Both groups received 
albumin at a dose of 4 grams per litre of ascitic 
fluid removed. Mean age was 53±12.5 in the group 
A while 52.8±10.1 in group B. hepatitis C was the 
predominant etiology in both the groups, seventy 
six patients (70.4%) in group A while seventeen 
patients (54.9%) in group B followed by hepatitis 
B, seventeen patients (15.7%) in group A and six 
patients (19.3%) in group B. Majority of patients 
were in Child Turcotte Pugh score of class C, 76% 
and 71% in group A and group B respectively. 
(Table-I)
 There was a rise in serum creatinine 6-10 days 
post LVP in group B from 1.11 ± 0.23 to 1.41±0.94 
as compared to the group A 1.04 ± 0.24 pre LVP 
to 1.07 ± 0.35 post LVP; but the difference did not 
reach statistical significance (P value 0.35).Similarly 
the difference in serum sodium level from baseline 
to 6-10 days post LVP also did not reach statistical 
significance. (Table-II)
 Five (4.62%) patients in the group A while Two 
(6.45%) patients in the group B had an increase of 
serum creatinine level of >0.5 mg/dl. Similarly, 
hyponatremia i.e. serum sodium <5 meq/lit from 
the baseline was observed in nine patients (8.33%) 
in the group A while three patients (9.67%) in 
the group B respectively. Three patients (2.3%) 
in group A and one patient (3.22%) in group B 
had transient hypotension which resolved by 
transiently stopping the ascitic drainage. None of 
the patients had abdominal wall hematoma or any 
other complication during the procedure.
DISCUSSION
 LVP in cirrhotic patients with ascites without 
volume expansion leads to complex circulatory 
abnormalities termed PICD which is clinically 
manifested by renal impairment, reaccumulation of 
ascites and shortened survival.14 In the initial phase 
post LVP there is an increase in cardiac output and 
stroke volume accompanied by a deactivation of 
the renin angiotensisn and sympathetic nervous 
system. This early phase is followed by a late phase 
in which there is an increase in the sympathetic and 
vasoconstrictor systems. It was also observed that 
these neurohumoral changes are associated with a 
decrease in systemic vascular resistance led to the 
conclusion that an accentuation of vasodilation is 
responsible for PICD in cirrhotic patients.6-8 This 
circulatory disturbance post LVP not only causes the 
hemodynamic alterations but is also responsible for 
worsening renal function, dilutional hyponatremia, 
increased accumulation of ascites and decreased 
survival.15 Various agents have been tried post 
LVP albeit with variable success to prevent PICD 
related complications mainly the renal impairment. 
Amongst those albumins has been found to be most 
effective.16-18
 Trials have also shown that when paracentesis 
of less than 6 litres is performed, the incidence of 
complications is the same irrespective of the plasma 
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Table-I: Shows the baseline characteristics
of the two groups.
     Group A     Group B P value
 (Albumin 25gm) (Albumin 50gm)
      (n=108)       (n=31) 
Age(yrs) 53.2 ± 11.2 52.8±  10.1 0.47
Gender (M/F) 58/50 15/16 0.68
Etiology
Hepatitis C 76(70.4%) 17(54.9%) ----
Hepatitis B 17(15.7%) 6(19.3%)
Non B Non C 15(13.9%) 8(25.8%) 
T.Bilirubin 4.5±   5.0 4.9 ±   5.8 0.69
  (mg/dl)
Albumin (g/l) 2.16±    0.42 2.29±   0.51 0.13
Prothrombin 18.4  ± 5.08 19.36 ±   5.79 0.08
  time
Child score 11 ± 2 11±2 0.24
Child Class
B 26(24.1%) 9(29%) 0.64
C 82(75.9%) 22(71%) 
Creatinine 1.04±  0.24 1.11± 0.23 0.15
  (mg/dl)
Sodium 130  ±  5.6 127.6  ±  5.8 0.01
 `(meq/lit)
Volume of 6.2± 1 10.4±1.5 ––
  ascitic fluid drained
Table-II: Changes in serum creatinine and sodium pre and post LVP.
 Group A (25gram Albumin) (n=108) Group B (50gram Albumin) (n=31) P value
  Pre LVP Post LVP Pre LVP Post LVP
Serum Cr (mg/dl) 1.04± 0.24 1.07±0.35 1.11±   0.23 1.41± 0.94 0.35
Sodium (meq/lit) 130  ± 5.6 129.6±5.9 127.6 ±  5.8 128 ±6.2 0.14
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expander used but when LVP of more than or equal 
to 6 liters is performed, Albumin is superior as 
compared to other plasma expanders.5,19,20 However 
albumin is very expensive. Initial studies done 
on this aspect used albumin at a dose of 8 gram/
liter. There is only scarce data so far that compared 
albumin at a lower dose than conventionally used.
In our study we did not find any statistically 
significant difference in the frequency of renal 
dysfunction and hyponatremia in the two groups 
at a dose of 4 grams albumin per litre of ascitic fluid 
drained. By definition, renal impairment occurred 
in five patients in group A and two patients in group 
B which were statistically not significant. Prior 
studies using a higher dose of albumin showed a 
similar statistically insignificant difference of renal 
dysfunction post LVP.21
 This finding has important bearing both from 
clinical and financial point of view. If this point is 
further proven in prospective randomized clinical 
trials it means that these patients can easily be 
managed with a lower dose of albumin without 
putting them at increased risk of renal failure.
 Serum creatinine is also a part of the model for 
end stage liver disease (MELD) score which predicts 
short term mortality in a decompensated cirrhotic 
patient. A higher serum creatinine implies a high 
MELD and vice versa. Moreover studies have shown 
that even after the post transplantation incidence 
of renal dysfunction depends on pretransplant 
kidney function.22 Hence, stabilization of renal 
function is very important in cirrhotic patients. 
The integral part in diagnosing PICD is increase 
in serum renin levels observed 5-6 days after 
paracentesis; since our study was retrospective we 
could not obtain serum renin levels in our patients. 
However the clinical manifestation of PICD is renal 
dysfunction and hyponatremia, which were well 
captured in our study. We segregated our patients 
into two groups based on the amount of albumin 
given. Since this was a retrospective study the two 
groups were not equally divided in number of 
patients. It is well known that if a larger volume of 
ascites is removed the greater is the chance of PICD 
and subsequent renal dysfunction.5 It is however, 
interesting to note that group B in our study in 
which the mean amount of ascites drained was 10 
liters the rate of renal dysfunction was the same as 
in group A in which lesser amount of ascitic fluid 
was drained. Similarly, hyponatremia i.e. serum 
sodium <5 meq/lit from the baseline was observed 
in nine patients (8.33%) in the group A  while three 
patients (9.67%) in the group B respectively which 
is consistent with the previous study done by Carlo 
Alessandria et al.21
CONCLUSION
 The results of this study suggested that treatment 
with low dose albumin i.e. 4 grams per litre of 
ascitic fluid drained is effective and safe in the 
prevention of renal impairment after large volume 
paracentesis in cirrhotic patients with tense ascites. 
However, any final recommendation regarding the 
exact dosage of albumin will require prospective, 
randomized control trials incorporating serum 
renin as an outcome parameter along with renal 
impairment and hyponatremia.
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